Company intelligence / Profile preview
TransCode Therapeutics, Inc.
Boston, Massachusetts, United Statestranscodetherapeutics.com ↗
- Ownership
- Public · RNAZ
- Employees
- ~7
- Development stage
- Phase 1
01
Overview
TransCode's lead candidate TTX-MC138 is currently in Phase 1 clinical trials with 3 cohorts completed. No significant safety or dose limiting toxicities have been reported in any of the trial's nine patients. PK data from Cohorts 1 and 2 is consistent with preclinical and Phase 0 trial results, showing evidence of pharmacodynamic activity with 66% inhibition of miR-10b at 24 hours after infusion.
- Therapeutic areas
- Oncology
- Modalities
- RNA therapeuticsRNAimiRNA modulatorsCRISPR/Cas9mRNAAntisense oligonucleotides (ASO)
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Request access →03
Partnerships
The University of Texas M.D. Anderson Cancer CenterAkribion Genomics
04
Financials
- Market cap
- $2M
- Total revenue
- $0
- Enterprise value
- $-5.7M
Beyond the preview
Go deeper on TransCode Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TransCode Therapeutics, Inc..